The Chronic Heart Failure Therapeutics Market is Forecast to Show Significant Growth Until 2019

London, England -- (SBWIRE) -- 03/30/2012 -- The global Chronic Heart Failure (CHF) therapeutics market, valued at $3,171.3m in 2006, grew at a Compound Annual Growth Rate (CAGR) of 4.0% to $3,849.9m in 2011. GlobalData's analysis suggests that the global CHF therapeutics market will grow at a CAGR of 3.1% during the forecast period to $4,918.4m by 2019. This growth will be primarily due to the expected launch of LCZ696 in 2015. The treatment-seeking population is expected to grow due to increased life expectancy and awareness of health among patients, as well as growth in the aging population more susceptible to Acute Heart Failure (AHF). Competition in the CHF therapeutics market is weak, as it is dominated by generic drugs such as beta-blockers (metropolol), diuretics (furosemide, spironolactone), digoxin, carvedilol and ramipril. Diovan (valsartan) is the only branded product, but it is expected to lose its patent protection in 2012 in the US.

GlobalData's analysis shows that the current CHF therapeutics market is dominated by generics, which do not treat the underlying cause of the disease. Digoxin, ramipril, carvedilol, metoprolol and Diovan are examples of drugs used to manage the symptoms of CHF, but none have disease-modifying mechanisms.

GlobalData's analysis shows that there are 41 molecules under development for the treatment of CHF. Of these, 78% are First-in-Class (FIC).

There are 10 molecules in Phase III, comprising 25% of the CHF therapeutics pipeline. Of these, 80% are FIC and are being developed for the treatment and management of CHF. LCZ696, a FIC molecule in Phase III, is intended to improve cardiac function in CHF patients. Additionally, lixivaptan, Aranesp (darbepoetin alfa), recombinant human neuregulin-1, Tekturna (aliskiren), and its Fixed Dose Combinations (FDCs) are being investigated to manage early stage CHF patients.

For Sample Pages, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?ID=Chronic-Heart-Failure-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&companyID=sbwire

There are 18 molecules in Phase II, accounting for 45% of the CHF therapeutics pipeline. The majority are being clinically tested for safety and efficacy in improving cardiac function. Phase I of the CHF pipeline accounts for only five molecules, or 12% of the pipeline. The Preclinical Phase contains five molecules, or 12%, and the Discovery Phase comprises three molecules, or 5% of the pipeline.

The pipeline assessment suggests that the CHF therapeutics pipeline is strong, with 30 FIC molecules under development, some of which stand a good chance of becoming the standard first-in-line therapy for the treatment and management of CHF.

Stem cell therapy is capable of significantly improving the CHF treatment pattern. The stem cell therapies in the pipeline will restore cardiac muscle function by regenerating and strengthening the heart muscle cells, potentially improving quality of life for CHF patients

Industry analysis specialist, GlobalData, has released its new report, "Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information on the global CHF therapeutics market, and analyzes a number of key areas. It identifies the key trends shaping and driving the global CHF therapeutics market and provides insights into the current competitive landscape and emerging companies. Most importantly, the report provides valuable insights into the pipeline products within the global CHF sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts

For further details, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/Report.aspx?ID=Chronic-Heart-Failure-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare&companyID=sbwire

Visit our report store: http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com
North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Middle East and Africa Leads the World in Terms of FPSO-based Capacity

London, England -- (SBWIRE) -- 03/29/2012 -- The global Floating Production Storage and Offloading (FPSO) market is dominated by the Middle East and Africa, accounting for nearly a third of the global FPSO-based crude oil and natural gas production capacity of 5,197.01 million barrels of oil equivalent (MMboe) in 2011. South and Central America and Asia-Pacific contribute 27.3% and 21.8%, respectively, to the global FPSO-based production capacity.

Out of the 26 countries using FPSO vessels for offshore production, Brazil, Angola and Nigeria are the three largest aggregaters of FPSO-based crude oil and natural gas production capacity worldwide. These three countries collectively contribute about half of the total FPSO-based crude oil and natural gas production capacity in the world.

At the end of 2011, there were 139 active FPSOs across the globe with 94 companies holding equity stakes in them. In terms of total FPSO-based crude oil and natural gas production capacity, Petrole Brasileiro S.A., ExxonMobil Corporation and Total S.A. position are the dominant companies in the global market. These companies together contribute about 29.2% of the global FPSO-based oil and gas production capacity

For Sample Pages, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?ID=Floating-Production-Storage-and-Offloading-%28FPSO%29-Industry-Global-Market-Analysis-Competitive-Landscape-and-Planned-Projects-to-2015&Title=Energy_and_Utilities&ReportType=Industry_Report&companyID=sbwire

The Brazilian national oil company Petroleo Brasileiro S.A. is the largest market player globally, in terms of FPSO-basd oil and gas production capacity, with 703.59 MMboe of the production capacity. The total equity-weighted FPSO-based crude oil and natural gas production capacity of Petroleo Brasileiro S.A. accounts for about 13.5% of the total production capacity of FPSOs globally.

For 2012 to 2015, Brazil has planned the largest FPSO-based crude oil and natural gas production capacity expansion among all the countries.

Therefore, based on current statistics, Brazil, which currently has the largest FPSO-based crude oil and natural gas production capacity, is expected to continue to be the market leader in the FPSO industry in 2015.

Brazil has huge offshore reserves. Its pre-salt discoveries have provided a major boost to the FPSO industry. Brazil's Petroleo Brasileiro S.A. has planned to add 12 FPSOs during 2012 to 2015. This will increase Brazil's FPSO-based annual production capacity to 1,635.14 MMbbl of crude oil and 1,231.35 billion cubic feet (bcf) of natural gas. This is the highest production capacity expansion planned by any country for the period.

FPSO vessels can be moved and moored in shallow, deep and ultra-deep waters. These vessels can be designed to withstand and operate in harsh environmental conditions in the sea. If required, an FPSO can be disconnected with a day's notice and sailed to a safer location to avoid the damage caused by adverse weather. This mobility of FPSOs can help oil and gas companies operating in tough environmental conditions to avoid monetary losses arising from such damage.

"Floating Production Storage and Offloading (FPSO) Industry - Global Market Analysis, Competitive Landscape and Planned Projects to 2015", is the latest report from GlobalData, the industry analysis specialist, that provides an in-depth analysis of the global FPSO industry to 2015.

The report details all the major countries, major companies and FPSOs in the various regions of the world. The report also provides key trends and challenges in the global FPSO market and plans for FPSO deployments in different countries globally. It also details the competitive landscape globally, and details the operations of the major FPSO companies.

For further details, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/Report.aspx?ID=Floating-Production-Storage-and-Offloading-%28FPSO%29-Industry-Global-Market-Analysis-Competitive-Landscape-and-Planned-Projects-to-2015&ReportType=Industry_Report&coreindustry=ALL&Title=Energy_and_Utilities&companyID=sbwire

Visit our report store: http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com
North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Global Bioethanol Market – Government Incentives and Fuel Demand to Boost Bioethanol Market

London, England -- (SBWIRE) -- 03/29/2012 -- Global bioethanol production started in 2003 with 33,514 million liters and grew to 105,608 million liters by 2011 at a CAGR of 15.4%. This was primarily due to government support in the form of subsidies. The blending targets and excise tax credit schemes has encouraged the growth of global bioethanol market National targets in Canada has helped to grow the bioethanol market whereas the blending targets has helped the growth of Chinese bioethanol market. The global production is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.4% during 2011-2020, reaching 154,962 million liters in 2020.

The global biodiesel production started in 2005 with 4,854 million liters and grew to 23,579 million liters by 2011 at a CAGR of 30.1%. Environmental concerns and rising energy security issues will increase the growth of biodiesel and the government support in the form of subsidies will further boost the biodiesel market. By 2020, global biodiesel production is expected to reach 41,917 million liters at a CAGR of 6.6% over 2011-2020.

In 2011, coarse grains accounted for the majority of feedstock used in the production of bioethanol followed by sugarcane. Wheat, molasses, non-agricultural feedstock, sugar beet and other forms of feedstock are also used for the global production of bioethanol.

For Sample Pages, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?ID=Biofuels-%28Biodiesel-and-Bioethanol%29-Market-Global-Production-Regulations-Competitive-Landscape-and-Key-Country-Analysis-to-2020&Title=Alternative_Energy&ReportType=Industry_Report&companyID=sbwire

The global bioethanol trade increased from 1,257 million liters in 2006 to 1,689 million liters in 2007 and 1,754 million liters by 2010. The US contributed significantly to the global bioethanol trade in 2010. The key global bioethanol exporters in 2010 were the US, Pakistan, the Netherlands, France, and Belgium. In 2010, the global biodiesel trade increased to 17,950 million liters from 14,927 million liters in 2009. Countries like Germany and China have considerable biodiesel production capacities which they use to export biodiesel to other countries. The key global biodiesel exporters in 2010 were Germany, China, the Netherlands, Argentina, Belgium and the US.

The production of bioethanol in Germany began in 2004 with 25 million liters. Bioethanol production in Germany is expected to grow at a CAGR of 69.6%, reaching 1,010 million liters in 2011. Bioethanol production is forecast to grow at a CAGR of 12.3% during 2011-2020, reaching 2,873 million liters in 2020. The production of biodiesel started in 2002 with 534 million liters. Since then, the biodiesel production has grown at a CAGR of 21.5% and is expected to reach 3,090 million liters in 2011. The production is forecast to grow at a CAGR of 3.5% during 2011-2020, reaching 4,205 million liters in 2020.

"Biofuels (Biodiesel and Bioethanol) Market – Global Production, Regulations, Export-Import Analysis and Key Country Analysis to 2020" is the latest report from GlobalData, the industry analysis specialists that offer comprehensive information and understanding of the biofuels industry.

The research provides an understanding of the technology, key drivers and challenges in the global biofuels market. The report provides detail overview on biofuels technology which includes bioethanol and biodiesel production process. The report provides biofuels production during the historical (2001-2010) and forecast period until 2020 for global and key countries such as Germany, France, Spain, China, Thailand, India, the US, Canada and Brazil. Key countries section in the report also covers key regulations supporting biofuels market development and biofuels import-export data for 2010.

For further details, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/Report.aspx?ID=Biofuels-%28Biodiesel-and-Bioethanol%29-Market-Global-Production-Regulations-Competitive-Landscape-and-Key-Country-Analysis-to-2020&ReportType=Industry_Report&coreindustry=ALL&Title=Alternative_Energy&companyID=sbwire

Visit our report store: http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com
North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Global Wound Closure Devices Market is Forecast to Reach $4.6 Billion by 2018

London, England -- (SBWIRE) -- 03/29/2012 -- The global wound closure devices market was valued at $3.3 billion in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.9% to reach $4.6 billion in 2018. The market is expected to be driven by the significant increase in the number of surgeries, especially cosmetic, cardiovascular, orthopedic and laparoscopic surgeries, increase in the number of sports injuries, increase in the global elderly population and large number of road accidents in the emerging countries.

The US wound closure devices market was valued at $1.3 billion in 2011 and is expected to grow at a CAGR of 4.2% to reach $1.7 billion in 2018. The growth will be fuelled by a number of factors such as increase in the number of surgeries especially cosmetic surgeries, increase in elderly population of the country and technological innovations going on in the field of wound closure devices.

According to statistics released by the American Society for Aesthetic Plastic Surgery (ASAPS) in April 2011, the demand for plastic surgery procedures increased by 9% in 2010 and has grown by 155% since
1997. About 9.5 million plastic surgery procedures were performed in the US in 2010 and about 92% or 8.6 million of these procedures were performed on women. Breast augmentation, lipoplasty, abdominoplasty, eyelid surgery and breast reduction procedures were the most sought after procedures in the US in 2010. About $6.6 billion was spent by the Americans on cosmetic surgery procedures in 2010.

For Sample Pages, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?ID=Wound-Closure-Devices-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&Title=Medical_Devices&ReportType=Industry_Report&companyID=sbwire

In 2011, Covidien plc the leading player in the global wound closure devices market with a share of about 24%. The leadership of Covidien can be attributed to technology innovation, diversified global presence, extensive wound closure devices portfolio and strong financial performance. Covidien continues to invest in new and advanced technologies across all fields, which results in a strong and growing patent portfolio. Through research and development efforts, the company is committed to identifying, receiving and developing new technologies and innovative products. In addition to internal R&D initiatives, through licensing and developing agreements, equity investment and selective acquisition, the company intends to expand its technological capabilities and accelerate the development of new products.

Ethicon and Baxter International are the second and third leading players in the global wound closure devices market with market shares of 14% and 10% respectively.

According to the National Electronic Injury Surveillance System (NEISS), the number of sports injuries in the US increased from about 2.86 million in 2007 to more than 2.91 million in 2009. According to a paper published in the British Journal of Sports Medicine in October 2010, Platelet-Rich Plasma (PRP)

(also known as platelet-rich in growth factors, platelet-rich fibrin matrix, platelet-rich fibrin, fibrin sealant, platelet concentrate) is now being extensively used for the treatment of musculoskeletal injuries in sports. There are many studies which suggest that wound closure devices such fibrin sealants and hemostats can be successfully used in the treatment of sports related injuries.

GlobalData's new report, "Wound Closure Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018" provides key data, information and analysis on the global wound closure devices market. The report provides market landscape, competitive landscape and market trends information on the wound closure devices market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

For further details, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/Report.aspx?ID=Wound-Closure-Devices-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=ALL&Title=Medical_Devices&companyID=sbwire

Visit our report store: http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com
North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm